hosted by The Hospital for Sick Children and in partnership with the LiFE Consortium
April 28, 2018
Dr. Anita Villani The ‘Toronto Protocol’: a Toronto perspective
Dr. Olivier Caron Evaluation of whole-body MRI for early detection of caners in germline TP53 mutation carriers: results of the LIFESCREEN study
Dr. Sharon Savage Findings at baseline surveillance in LFS
Dr. Mary-Louise Greer Whole-body MRI in surveillance of LFS and other cancer predisposition syndrome
Dr. Andrea Doria Genotype and phenotype of cancers developing in LFS patients: an 18-year review in a tertiary pediatric hospital
Dr. Junne Kamihara Cancer screening in LFS: the Dana-Farber experience
Prof. Trevor Pugh Circulating tumor DNA as a molecular monitor for hereditary cancers
Dr. Ayelet Erez Implications from cancer metabolism to immunity
Dr. Curtis Harris Aging and cancer: p53 isoforms
Dr. Paul Hwang Insights into p53 biology by modeling a unique LFS mutation
Dr. Claire Wakefield Li-Fraumeni syndrome through the lens of pediatric practice: a review, and audit and family and professional perspectives
Dr. Jennifer Young Couples living together with LFS: coping styles and partner roles
Ms. Katherine Schneider Current genetic counseling dilemmas: dealing with the increasing complexity of TP53 results
Dr. Varda Rotter Role of wild-type p53 in normal stem cell regulation and mutant p53 deregulation in cancer stem cells – lessons from the LFS model
Dr. Ran Kafri Cancer prevention pharmacology: drug screen identifies candidates for cancer prevention in LFS
Dr. Klas Wiman Novel cancer therapy by targeting missense and nonsense mutant p53
Keynote Address: Dr. Arnold Levine A role for immunotherapy in p53 mutant cancers?
